MARKET

KYTX

KYTX

Kyverna Therapeutics
NASDAQ
7.00
+0.09
+1.30%
After Hours: 7.00 0 0.00% 18:27 12/18 EST
OPEN
7.08
PREV CLOSE
6.91
HIGH
7.30
LOW
6.58
VOLUME
4.50M
TURNOVER
--
52 WEEK HIGH
13.67
52 WEEK LOW
1.780
MARKET CAP
306.57M
P/E (TTM)
-1.8813
1D
5D
1M
3M
1Y
5Y
1D
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies
Seeking Alpha · 8h ago
Kyverna Therapeutics Announces $100 Million Public Offering
TipRanks · 16h ago
Kyverna Therapeutics Chief Technology Officer Karen Marie Walker Reports Disposal of Common Shares
Reuters · 1d ago
Kyverna Therapeutics (KYTX) Is Up 29.5% After Strong KYSA-8 Data And $100 Million Equity Raise
Simply Wall St · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
TipRanks · 1d ago
Crude Oil Rises Over 1%; General Mills Earnings Top Views
Benzinga · 1d ago
Kyverna Therapeutics announces pricing of $100M public offering
Seeking Alpha · 1d ago
More
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Webull offers Kyverna Therapeutics Inc stock information, including NASDAQ: KYTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYTX stock methods without spending real money on the virtual paper trading platform.